Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy
Phase 1 Study of Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After Post-transplantation Cyclophosphamide
This phase 1, single-center, open-label dose-escalation study will evaluate the safety, tolerability, and immune reconstitution effects of efineptakin alfa (rhIL-7-hyFc, NT-I7) administered after allogeneic hematopoietic cell transplantation (allo-HCT) in participants receiving post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Maria Urdiales Kouba
- Telefonnummer: 813-745-1218
- E-Mail: Maria.UrdialesKouba@moffitt.org
Studienorte
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center
-
Unterermittler:
- Melissa Alsina, MD
-
Unterermittler:
- Lia Perez, MD
-
Unterermittler:
- Doris Hansen, MD
-
Unterermittler:
- Rawan Faramand, MD
-
Unterermittler:
- Hien Liu, MD
-
Unterermittler:
- Omar Castaneda Puglianini, MD
-
Unterermittler:
- Michael Jain, MD
-
Unterermittler:
- Asmita Mishra, MD
-
Unterermittler:
- Taiga Nishihori, MD
-
Unterermittler:
- Nelli Bejanyan, MD
-
Unterermittler:
- Farhad Khimani, MD
-
Unterermittler:
- Aleksandr Lazaryan, MD
-
Unterermittler:
- Fabiana Perna, MD
-
Unterermittler:
- Joseph Pidala, MD
-
Unterermittler:
- Reshma Ramlal, MD
-
Hauptermittler:
- Sayeef Mirza, MD
-
Unterermittler:
- Alaa Ali, MD
-
Unterermittler:
- Deepakbabu Chellapanian, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- First allogeneic HCT with peripheral blood as the only graft source used for allo HCT.
- Diagnosis of hematologic malignancy eligible for allo-HCT.
- Only patients with plan for post-transplant cyclophosphamide based GVHD prophylaxis are eligible.
- Eligible donors include matched-related, matched-unrelated, mismatched unrelated, and HLA-haploidentical relatives with a shared HLA haplotype with the patient, determined by high-resolution DNA typing at HLA-A, -B, -C, and -DRB1 loci per standardof care practice as documented in the medical record.
- Granulocyte-colony stimulating factor (G-CSF)-mobilized donor peripheral blood hematopoietic cells were targeted to a CD34+ cell dose of 5 × 106/kg with a minimum accepted dose of 2 × 106 cells per kg and a maximum dose of 10 × 106 cells per kg.
- Patient age ≥18 years at time of consent.
- Karnofsky performance status of ≥80% for the myeloablative and ≥60% for the nonmyeloablative (NMA) regimens.
- Patients with documented engraftment but require granulocyte-colony stimulating factor (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection are eligible with G-CSF washout at least 14 days prior to Efineptakin Alfa.
- Participants must have adequate organ and marrow function
- Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Absence of dyspnea or hypoxia (< 90% of saturation by pulse oximetry on room air).
- The effects of rh-IL-7 on the developing human fetus are unknown. For this reason and because immunomodulatory agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for an additional four months after completion of the last study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Progressive or advanced hematological malignancy.
- Patients with acute GVHD requiring systemic immunosuppression within the first 30 days (to avoid confounding lymphopenia from GVHD and steroid therapy). (Patients receiving GVHD prophylaxis will be allowed on this study).
- Patients who fail to achieve engraftment by day 30 post-HCT (for safety concerns, and due to major interventions including second HCT done in the setting of engraftment failure).
- History of Epstein-Barr virus (EBV) associated lymphoproliferation.
- Active uncontrolled viral, bacterial or fungal infection.
- History of autoimmune disease.
- Receiving systemic corticosteroid therapy (budesonide is allowed).
- Uncontrolled hypertension as defined by Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg, confirmed by repeat measurement after appropriate rest.
- Corrected QT (QTcF) prolongation (QTcF > 470 ms) or prior history of significant arrhythmia or electrocardiogram (ECG) abnormalities.
- Presence of donor-specific antibodies.
- Inability or unwillingness to provide signed informed consent or comply with the study requirements.
- Participants who have not recovered from non-hematologic adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), with the exception of alopecia.
- Participants who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rh-IL7 or other agents in the conditioning or GVHD prophylaxis regimen.
- Participants receiving any medications or substances that are prohibited while on study (see section 6.7.). As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
- Participants with psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or nursing women will be excluded from this study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Efineptakin Alfa (rhIL-7-hyFc)
Participants will receive a single intramuscular dose of efineptakin alfa (NT-I7, rhIL-7-hyFc) on Day +60 after allogeneic hematopoietic cell transplantation. Dose assignment will follow a phase 1 dose-escalation design with dose levels of 240 μg/kg, 480 μg/kg, and 720 μg/kg. |
Single intramuscular administration on Day +60 after allo-HCT. Dose escalation includes 240 μg/kg, 480 μg/kg, and 720 μg/kg. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recommended phase II dose (RP2D)
Zeitfenster: Up to 90 days
|
Determine the recommended phase 2 dose (RP2D) of efineptakin alfa. |
Up to 90 days
|
|
Absolute Lymphocyte Count Recovery
Zeitfenster: Up to 90 days
|
Proportion of participants achieving an absolute lymphocyte count (ALC) ≥1,000 cells/mm³ at Day +90 following transplantation. |
Up to 90 days
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Occurrence of infections
Zeitfenster: Up to 100 days
|
Defined as developing (or experiencing re-activation) of a viral, bacterial, or fungal infection by Day +100. |
Up to 100 days
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Sayeef Mirza, MD, Moffitt Cancer Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- MCC-23978
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .